-
公开(公告)号：US20120209000A1
公开(公告)日：2012-08-16
申请号：US13450784
申请日：2012-04-19
IPC分类号： C07D471/22
CPC分类号： C07D471/14
摘要： The present invention is directed to a compound of the formula: The compound is useful as an intermediate for preparing an HIV drug.
摘要翻译： 本发明涉及下式的化合物：该化合物可用作制备HIV药物的中间体。
-
公开(公告)号：US20120184734A1
公开(公告)日：2012-07-19
申请号：US13378334
申请日：2010-06-14
申请人： Toshiyuki Akiyama , Kenji Takaya , Makoto Kawai , Yoshiyuki Taoda , Minako Mikamiyama , Kenji Morimoto , Chika Kageyama , Kenji Tomita , Hidenori Mikamiyama , Naoyuki Suzuki
发明人： Toshiyuki Akiyama , Kenji Takaya , Makoto Kawai , Yoshiyuki Taoda , Minako Mikamiyama , Kenji Morimoto , Chika Kageyama , Kenji Tomita , Hidenori Mikamiyama , Naoyuki Suzuki
IPC分类号： C07D498/14 , C07D471/14 , C07D471/04
CPC分类号： C07D471/04 , A61K31/53 , C07D471/14 , C07D487/14 , C07D487/20 , C07D498/14
摘要： This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
摘要翻译： 本发明提供具有抗病毒活性的化合物，特别是抑制流感病毒的活性，更优选提供具有cap依赖性内切核酸酶抑制活性的取代的3-羟基-4-吡啶酮衍生物。
-
3.发明申请公开(公告)号：US20110282055A1
公开(公告)日：2011-11-17
申请号：US13128992
申请日：2009-12-08
IPC分类号： C07D498/14 , C07D471/22
CPC分类号： C07D498/14 , A61K31/351 , A61K31/4412 , C07D213/803 , C07D213/81 , C07D471/22 , C07D487/22 , Y02P20/55
摘要： A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
摘要翻译： 合成方法通过溴化得到化合物1-1的早期环附着，得到化合物II-II，由此可以合成最终产物例如AA。 特别地，在产生附加环Q之前附着了含2,4-二氟苯基的侧链。
-
![Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines](/abs-image/US/2012/05/22/US08183372B2/abs.jpg.150x150.jpg)
4.发明授权Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines 有权取代的9,11-二氧代-2,3,4a，5,9,11,13,13a-八氢-1H-吡啶并[1,2-a]吡咯并[1'，2'：3,4]咪唑并[1 ，2-d]吡嗪公开(公告)号：US08183372B2
公开(公告)日：2012-05-22
申请号：US13055046
申请日：2009-07-23
IPC分类号： C07D241/36
CPC分类号： C07D471/14
摘要： The present invention is directed to a process for the preparation of a compound of formula 1b which compound is useful as a prodrug of HIV integrase inhibitors and therefore is useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. The process includes the steps of a) brominating a compound of formula P-7 to form a compound of formula P-8, b) treating a compound of formula P-8 with NaIO4 to form a compound of formula P-9, c) reacting a compound of formula P-9 with [(2R)-pyrrolidinylmethyl]amine of formula to form a compound of formula P-10, d) reacting a compound of formula P-10 with 2, 4-difluorobenzylamine to form a compound of formula P-11, e) treating a compound of P-11 with palladium on carbon and ammonium hydroxide to form a compound of formula 1a, and f) treating a compound of formula 1a with NaOH and ethanol to form a compound of formula 1b. The structures of the above mentioned compounds are disclosed in the specification.
摘要翻译： 本发明涉及一种制备式1b化合物的方法，该化合物可用作HIV整合酶抑制剂的前药，因此可用于抑制HIV复制，预防和/或治疗HIV感染， 和治疗艾滋病和/或ARC。 该方法包括以下步骤：a）将式P-7化合物溴化以形成式P-8的化合物，b）用NaIO 4处理式P-8的化合物以形成式P-9的化合物，c） 使式P-9的化合物与式的[（2R） - 吡咯烷基甲基]胺反应形成式P-10的化合物，d）使式P-10的化合物与2,4-二氟苄胺反应，形成化合物 式P-11，e）用钯碳和氢氧化铵处理P-11化合物以形成式1a化合物，和f）用NaOH和乙醇处理式1a化合物以形成式1b化合物。 上述化合物的结构在说明书中公开。
-
5.发明申请POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY 有权具有HIV整合酶抑制活性的多环碳酰胺基衍生物公开(公告)号：US20120115875A1
公开(公告)日：2012-05-10
申请号：US13352686
申请日：2012-01-18
IPC分类号： A61K31/4985 , A61P31/18 , C07D498/14
CPC分类号： C07D498/14 , A61K9/0053 , A61K31/4985 , A61K31/519 , A61K31/5365 , A61K31/551 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/22 , C07D498/04 , C07D498/20 , C07D498/22
摘要： The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
摘要翻译： 本发明提供下述新型化合物（I），具有抗病毒活性，特别是HIV整合酶抑制活性，以及含有该化合物（I）的药物，特别是抗HIV药物，以及方法和 中间体。 （其中Z 1为NR 4; R 1为氢或低级烷基; X为单键，选自O，S，SO，SO 2和NH的杂原子基团，或杂原子基团可插入的低级亚烷基或低级亚烯基） R2是任选取代的芳基; R 3是氢，卤素，羟基，任选取代的低级烷基等;和R 4和Z 2部分一起形成环，形成多环化合物，包括例如三环或四环化合物。
-
6.发明授权Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness 有权取代的5-羟基-3,4,6,9,9a，10-六氢-2h-1-氧杂-4a，8a-二氮杂 - 蒽-6,10-二酮公开(公告)号：US08129385B2
公开(公告)日：2012-03-06
申请号：US11919386
申请日：2006-04-28
IPC分类号： A61K31/495
CPC分类号： C07D498/14 , A61K9/0053 , A61K31/4985 , A61K31/519 , A61K31/5365 , A61K31/551 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/22 , C07D498/04 , C07D498/20 , C07D498/22
摘要： The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-diones useful as anti-HIV agents. The compounds have the formula: Z═O; R20, R21, R22, R23, R24 and R25 independently are hydrogen, C1-C8 alkyl, (C6-C14)aryl-(C1-C8)alkyl, C6-C14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; RX is hydrogen; R14 is hydrogen or optionally substituted lower alkyl; R3 is hydrogen; R1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及一类用作抗体的取代的5-羟基-3,4,6,9,9a，10-六氢-2H-1-氧杂-4a，8a-二氮杂 - 蒽-6,10-二酮 -HIV代理 化合物具有下式：Z = O; R 20，R 21，R 22，R 23，R 24和R 25独立地是氢，C 1 -C 8烷基，（C 6 -C 14）芳基 - （C 1 -C 8）烷基，C 6 -C 14芳基或烷氧基; 由*表示的不对称碳的立体化学显示R-或S-构型，或其混合物; RX是氢; R 14是氢或任选取代的低级烷基; R3是氢; R1是氢或低级烷基; R是卤素; m为1,2或3; 或其药学上可接受的盐。
-
公开(公告)号：US20100204237A1
公开(公告)日：2010-08-12
申请号：US12662515
申请日：2010-04-21
IPC分类号： A61K31/506 , A61K31/519 , C07D487/04 , C07D403/04 , C07D413/04 , C07D417/14 , C07D413/14
CPC分类号： C07D417/14 , C07D401/04 , C07D405/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D487/04
摘要： Compounds of Formula (1), pharmaceuticals containing the same, especially anti-HIV agents having anti viral activity, especially inhibitory activity against HIV integrase, wherein X represents either one of the following groups: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z1 and Z3 each is independently a single bond, O, S, S(═O) or SO2; Z2 is a single bond, lower alkylene or lower alkenylene; Ar is optionally substituted aryl or optionally substituted heteroaryl; R1 is lower alkyl, substituted lower alkyl or the like; R2 is a hydrogen atom or optionally substituted lower alkyl; or R1 and R2 may form, together with an adjacent atom, an optionally substituted heterocyclic ring, a pharmaceutically acceptable salt or a solvate thereof.
-
公开(公告)号：US08846929B2
公开(公告)日：2014-09-30
申请号：US12712042
申请日：2010-02-24
申请人： Kouki Fuchino , R. Richard Goehring , Bin Shao , Yoshiyuki Taoda , Naoki Tsuno , John William Frank Whitehead , Jiangchao Yao
发明人： Kouki Fuchino , R. Richard Goehring , Bin Shao , Yoshiyuki Taoda , Naoki Tsuno , John William Frank Whitehead , Jiangchao Yao
IPC分类号： C07D295/00
CPC分类号： C07D451/14 , A61K31/498 , C07D401/04 , C07D401/14 , C07D451/04 , C07D471/08 , C07D471/14 , C07D487/04 , C07D498/08 , C07D519/00
摘要： The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.
摘要翻译： 本发明涉及取代的喹喔啉型哌啶化合物，包含有效量的取代的喹喔啉型哌啶化合物的组合物和治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量 的取代的喹喔啉型哌啶化合物。
-
9.发明授权公开(公告)号：US08624023B2
公开(公告)日：2014-01-07
申请号：US13128992
申请日：2009-12-08
IPC分类号： C07D498/14 , C07D471/22
CPC分类号： C07D498/14 , A61K31/351 , A61K31/4412 , C07D213/803 , C07D213/81 , C07D471/22 , C07D487/22 , Y02P20/55
摘要： A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
摘要翻译： 通过溴化将早期环连接提供给化合物I-1的合成方法，得到化合物II-II：由此可以合成最终产物如AA。 特别地，在产生附加环Q之前附着了含2,4-二氟苯基的侧链。
-
公开(公告)号：US20130197219A1
公开(公告)日：2013-08-01
申请号：US13824723
申请日：2011-09-21
申请人： Chika Takahashi , Hidenori Mikamiyama , Toshiyuki Akiyama , Kenji Tomita , Yoshiyuki Taoda , Makoto Kawai , Kosuke Anan , Masayoshi Miyagawa , Naoyuki Suzuki
发明人： Chika Takahashi , Hidenori Mikamiyama , Toshiyuki Akiyama , Kenji Tomita , Yoshiyuki Taoda , Makoto Kawai , Kosuke Anan , Masayoshi Miyagawa , Naoyuki Suzuki
IPC分类号： C07D471/04 , C07F9/6561
CPC分类号： C07D471/04 , A61K31/4738 , C07D471/14 , C07F9/6561 , C07F9/65616
摘要： The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.027 秒)
